ARHGAP36 Activators
ARHGAP36 Activators are a class of compounds that can influence cellular processes and signaling pathways to indirectly enhance the functional activity of ARHGAP36. ARHGAP36 is a GTPase-activating protein (GAP) for the Rho family of GTPases, particularly RhoA, and is involved in regulating the actin cytoskeleton. Compounds such as PDBu and LPA activate PKC and RhoA respectively, which can lead to an increase in ARHGAP36's GAP activity to counteract the effects of enhanced RhoA signaling and maintain cytoskeletal dynamics. Jasplakinolide and Calpeptin influence the actin cytoskeleton by promoting polymerization and inhibiting degradation, respectively, which may result in a compensatory upregulation of ARHGAP36 activity.
ML141, Y-27632, NSC23766, and Rhosin are inhibitors of various Rho GTPases and their associated pathways. By inhibiting Cdc42, ROCK, Rac1, and RhoA GEF interactions, these compounds disrupt the equilibrium of Rho GTPase signaling within the cell. The perturbation caused by these inhibitors can lead to an enhancement of ARHGAP36 GAP activity as part of the cellular response to re-establish homeostasis in actin cytoskeleton organization and cell motility. ITX3, by inhibiting the GEF activity of Trio, would require a balancing act by ARHGAP36 to maintain proper GTPase signaling. CCG-1423 inhibits RhoA transcriptional signaling, which may result in an upregulation of ARHGAP36 to adjust Rho GTPase activity. Lastly, Exoenzyme C3 inactivates Rho proteins, leading to an increased activity of ARHGAP36 to compensate for the loss of Rho GTPase function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Phorbol-12,13-dibutyrate | 37558-16-0 | sc-202285 | 1 mg | $124.00 | 3 | |
PDBu is a phorbol ester that mimics diacylglycerol (DAG), a physiological activator of Protein Kinase C (PKC). PKC activation can lead to changes in the actin cytoskeleton, which is a process that ARHGAP36 is known to influence through its Rho GTPase activating protein activity. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Lysophosphatidic acid (LPA) is a bioactive lipid that activates G-protein-coupled receptors, leading to RhoA activation. ARHGAP36 functions to deactivate RhoA, thus LPA-induced activation of RhoA can result in a compensatory enhancement of ARHGAP36 GAP activity. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and promotes actin polymerization, leading to altered cytoskeletal dynamics. ARHGAP36, as a Rho GTPase-activating protein, may be upregulated in response to maintain cytoskeletal balance. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Calpeptin is a calpain inhibitor that prevents the cleavage of cytoskeletal proteins, potentially leading to an increase in actin filament stability. This stability can indirectly enhance ARHGAP36 activity as the protein works to regulate actin cytoskeleton remodeling. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a selective inhibitor of Cdc42, a Rho GTPase involved in actin organization. Inhibition of Cdc42 can lead to compensatory activation of ARHGAP36 to rebalance the activity of Rho family GTPases within the cell. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that reduces the contractility of the actin-myosin cytoskeleton. ARHGAP36 may be upregulated to modulate the downstream effects of ROCK inhibition on cell shape and motility. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766 inhibits Rac1, another member of the Rho GTPase family, disrupting Rac1-dependent cell processes. This inhibition can enhance ARHGAP36 activity as the cell compensates for reduced Rac1 activity. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
Rhosin is a selective inhibitor of RhoA subfamily binding to guanine nucleotide exchange factors (GEFs), leading to reduced RhoA activation. ARHGAP36 activity can be enhanced as the cell attempts to adjust the regulation of Rho GTPases. | ||||||
ITX 3 | 347323-96-0 | sc-295214 sc-295214A | 10 mg 50 mg | $145.00 $615.00 | ||
ITX3 is a Trio inhibitor that specifically disrupts the GEF activity of Trio towards Rac1 and RhoG. The inhibition of Trio can result in an increased requirement for ARHGAP36 GAP activity to maintain cellular homeostasis of GTPase signaling. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 is an inhibitor of RhoA transcriptional signaling via the serum response factor (SRF) pathway. ARHGAP36 activity might be upregulated as a response to maintain the balance in RhoA-mediated signaling pathways. | ||||||